NRSN Stock Forecast & Price Target

NeuroSense Therapeutics is attractive fundamentally because PrimeC has already shown a differentiated multi-target mechanism that addresses shared drivers of neurodegeneration—neuroinflammation, autophagy dysfunction, miRNA dysregulation, and iron imbalance—rather than a single downstream symptom. In ALS, the program posted compelling Phase 2b PARADIGM results in 68 patients, including a primary biomarker win on TDP-43 (p=0.04 at month six; p<0.001 at month 18), a median survival of 36.3 months versus 21.4 months with crossover, and a 65% lower risk of death (HR=0.35), while remaining generally well tolerated. The company also has multiple shots on goal, with FDA-cleared Phase 3 PARAGON, a Health Canada NDS planned for late 4Q26, and early Alzheimer’s biomarker signals in 2Q26 that broaden PrimeC’s commercial opportunity beyond ALS.

NeuroSense Therapeutics is facing a cautious fundamental setup because its lead program, PrimeC, has seen key milestones pushed out to March 2027 for the Canadian NDS filing and mid-2027 for Phase 3 initiation, reducing near-term execution visibility. The company’s reliance on additional biomarker analysis, unresolved regulatory questions, and the need to secure funding before advancing PARAGON increases uncertainty, while 1H26 EPS of ($2.06) and just $0.2 million in cash underscore a fragile balance sheet. Compounding these issues are two live Nasdaq deficiencies with a September 29, 2026 cure deadline, raising delisting and financing risks that could further impair development progress.